Comparison of Drug Approvals in Europe Versus the United States: An Analysis of Discrepancies Between Drug Products Reviewed by EMA and FDA

Therapeutic Innovation & Regulatory Science
Robert W Makuch, Ruizhi Shi

Abstract

Regulators from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) do not always agree on interpretation of data for a drug's safety and efficacy. The authors compared all new molecular entities approved or rejected in a 5-year period from 2007 to 2011, identified where FDA and EMA reviews resulted in different regulatory decisions, and explored potential mechanisms for the discrepancies. Thirteen entities were associated with different regulatory decisions, and 2 drugs were withdrawn from their respective markets in 2010: one from the US (Mylotarg; gemtuzumab ozogamicin) and the other in Europe (Thelin; sitaxentan sodium). There are relatively few cases where FDA and EMA substantively differ with regard to product approvals and market withdrawals. It is likely that the scientific and cultural differences between FDA and EMA will continue to diminish over time, because these two agencies increasingly work together as pharmaceutical product development increasingly becomes a global endeavor.

References

Oct 3, 1998·BMJ : British Medical Journal·J D Kleinke, S Gottlieb
Jun 6, 2008·Journal of Clinical Pharmacology·Henry J MalinowskiTing Ong
Aug 12, 2010·Fundamental & Clinical Pharmacology·Michael DomanskiFaiez Zannad
Aug 17, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesco PignattiMichel Marty
Mar 7, 2012·Southern Medical Journal·James L FurgersonJennifer C Thompson
May 18, 2012·The New England Journal of Medicine·Nicholas S DowningJoseph S Ross
Jun 20, 2012·Statistics in Medicine·Thomas R Fleming, John H Powers
Jun 27, 2012·Critical Care : the Official Journal of the Critical Care Forum·Pradeep H Lakshminarayana, Jeremy M Kahn
Sep 12, 2012·Investigational New Drugs·Tetsuya TanimotoMasahiro Kami
Oct 31, 2012·OncoTargets and Therapy·Beth SherrillConnie Chen
Feb 7, 2013·JAMA : the Journal of the American Medical Association·Aaron S KesselheimJerry Avorn

❮ Previous
Next ❯

Citations

Nov 6, 2015·Journal of Korean Medical Science·Kye Hwa LeeJu Han Kim
Jun 24, 2016·Biotechnology Letters·Ray Bakhtiar
Feb 23, 2018·European Journal of Clinical Pharmacology·Minette-Joëlle ZeukengPascal Bonnabry

❮ Previous
Next ❯

Software Mentioned

Mylotarg

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.